[
    [
        {
            "time": "2018-01-02",
            "original_text": "Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Eli Lilly",
                    "PNC Financial"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "Jim Cramer Weighs in on Eli Lilly and Elizabeth Warren, Boeing's CEO and FedEx's Earnings",
            "features": {
                "keywords": [
                    "Jim Cramer",
                    "Eli Lilly",
                    "Elizabeth Warren",
                    "Boeing",
                    "FedEx"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "transportation"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Jim Cramer Weighs in on Eli Lilly and Elizabeth Warren, Boeing's CEO and FedEx's Earnings",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-12-31",
            "original_text": "Pharmaceutical Stocks Had a Rough Year. Here’s Why 2020 Could Be Better.",
            "features": {
                "keywords": [
                    "Pharmaceutical Stocks",
                    "Rough Year",
                    "2020 Outlook"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharmaceutical Stocks Had a Rough Year. Here’s Why 2020 Could Be Better.",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-09-12",
            "original_text": "Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Elizabeth Warren",
                    "PBMs",
                    "Insurance",
                    "Affordable Insulin"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-01-10",
            "original_text": "Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU",
            "features": {
                "keywords": [
                    "Dicerna",
                    "A1AT Candidate",
                    "Orphan Drug",
                    "EU"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-01-15",
            "original_text": "Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020",
            "features": {
                "keywords": [
                    "Lilly",
                    "Stock Up",
                    "Sales",
                    "Profit Outlook",
                    "2020"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-01-20",
            "original_text": "Eli Lilly Shares Climb; Morgan Stanley Upgrades Drugmaker to Overweight and Lifts Price Target",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Shares Climb",
                    "Morgan Stanley",
                    "Overweight",
                    "Price Target"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly Shares Climb; Morgan Stanley Upgrades Drugmaker to Overweight and Lifts Price Target",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-02-05",
            "original_text": "Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)",
            "features": {
                "keywords": [
                    "Lilly",
                    "TRIUMPH",
                    "Emgality",
                    "Real-World Evidence Study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-12-31",
            "original_text": "What Are Your Market Resolutions? Jim Cramer on Eli Lilly, FedEx and Boeing",
            "features": {
                "keywords": [
                    "Market Resolutions",
                    "Jim Cramer",
                    "Eli Lilly",
                    "FedEx",
                    "Boeing"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "transportation"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Are Your Market Resolutions? Jim Cramer on Eli Lilly, FedEx and Boeing",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]